©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2023; 11(17): 3993-4002
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3993
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3993
Elabela is a reliable biomarker for predicting early onset preeclampsia: A comparative study
Eham Amer Ali, Department of Chemistry and Biochemistry, Mustansiriyah University, Baghdad 10052, Iraq
Wassan Nori, Ban H Hameed, Department of Obstetrics and Gynecology, Mustansiriyah University, Baghdad 10052, Iraq
Alea Farhan Salman, National Central of Hematology, Mustansiriyah University, Baghdad 10052, Iraq
Taghreed S Saeed Al-Rawi, Department of Biochemistry, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq
Raid M Al-Ani, Department of Surgery/Otolaryngology, University of Anbar College of Medicine, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq
Author contributions: Ali EA and Nori W designed research and reviewed data, wrote and revised the manuscript; Salman AF and Hameed BH collected and analyzed the data; Al-Rawi TSS and Al-Ani RM did the literature review; Al-Ani RM was responsible for the final revision and drafting of the manuscript; and all the authors have read and agreed on the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Scientific-Ethical Committee of the Mustansiriyah University (Approval No. IRB126).
Informed consent statement: All pregnant gave written consent prior to enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets analyzed during the current study are available in the hospital’s “sheet patient records” and from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Corresponding author: Raid M Al-Ani, MBChB, N/A, Academic Editor, Consultant Physician-Scientist, Full Professor, Researcher, Science Editor, Department of Surgery/Otolaryngology, University of Anbar College of Medicine, University of Anbar College of Medicine, Al-Andalus, No. 41 Street, Ramadi City 31001, Anbar, Iraq. med.raed.alani2003@uoanbar.edu.iq
Received: March 18, 2023
Peer-review started: March 18, 2023
First decision: May 9, 2023
Revised: May 9, 2023
Accepted: May 15, 2023
Article in press: May 15, 2023
Published online: June 16, 2023
Processing time: 85 Days and 14.8 Hours
Peer-review started: March 18, 2023
First decision: May 9, 2023
Revised: May 9, 2023
Accepted: May 15, 2023
Article in press: May 15, 2023
Published online: June 16, 2023
Processing time: 85 Days and 14.8 Hours
Core Tip
Core Tip: Preeclampsia (PE) is a worldwide cause of increased maternal and perinatal morbidity; PE is divided into early-onset and late-onset subtypes. The precise pathophysiology of PE is obscured, and currently no treatment exists but to terminate pregnancy. Several researches seek a reliable biomarker to anticipate PE to mitigate its negative effects. Elabela (Ela), a recently discovered peptide hormone secreted by the fetus and human placenta; animal studies confirmed Ela’s critical role in maintaining blood pressure; its deficiency was linked to elevated blood pressure. The purpose of this study was to evaluate the accuracy of Ela in predicting PE based on the time of occurrence.